PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)
← catalyst calendarNCT06602271 · readout ≤ 12 d
Sponsored by Ensysce Biosciences (industry) · ENSC — their whole pipeline →. With Rho, Inc..
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
320estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-09 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Postoperative Pain, Acute
Interventions
- Drug: PF614 capsule
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPain NRS-R area under the curve through 48 hours (AUC4-48)
measured 4-48 hours
Publications
- PMID 28345745 — cited as background
- PMID 38511523 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ENSC's whole pipeline · Catalyst calendar · Every registered study · What changed